See the DrugPatentWatch profile for Vemlidy
What is Vemlidy’s “primary completion date”?
Vemlidy (tenofovir alafenamide) has multiple clinical studies, and the “primary completion date” depends on the specific trial and its sponsor/registry entry. The term is used for the date when study participants complete the study’s primary endpoints, but it is not a single, universal date for the whole drug.
To give the correct primary completion date, you need the exact trial identifier (e.g., NCT number) or the specific study record you mean.
Where you can find it (and what to look for)
If you’re looking at a clinical trial listing (commonly on ClinicalTrials.gov or a similar registry), search within that specific trial page for:
- “Primary Completion Date” (or “Primary completion date”)
- The trial’s NCT number (or equivalent)
Which primary completion date are you referring to?
If you share any of the following, I can pinpoint the exact “primary completion date” from the relevant record:
- The NCT number for the Vemlidy study
- A link to the trial page you’re looking at
- The study name/purpose (e.g., HBV, HBeAg status, phase)
Quick clarification that prevents common mix-ups
“Primary completion date” for Vemlidy can differ across:
- Different indications (chronic HBV vs other studies)
- Different phases (Phase 2 vs Phase 3)
- Different regions or protocol amendments
Reply with the NCT number or the link to the trial record, and I’ll give the exact date.